公开(公告)号：US09110082B2

公开(公告)日：2015-08-18

申请号：US13512061

申请日：2010-11-22

申请人： Sriram Sathyanarayanan ,  Christopher Winter ,  Youyuan Xu

发明人： Sriram Sathyanarayanan ,  Christopher Winter ,  Youyuan Xu

IPC分类号： G01N33/68 ,  A61N5/02 ,  A61N5/10 ,  C12Q1/68 ,  G01N33/50 ,  A61K39/395 ,  A61K45/06 ,  A61N5/06

CPC分类号： G01N33/6893 ,  A61K39/39558 ,  A61K45/06 ,  A61N5/02 ,  A61N5/06 ,  A61N5/10 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/136 ,  G01N33/5044 ,  G01N33/5091 ,  G01N2333/475

摘要： The present invention relates to methods for treating a dalotuzumab responsive cancer, in a patient, comprising determining the expression level of liver kinase B1 (LKB1), in a cancer cell from the patient, and when said expression is determined to be lower than that of a control cell; administering, to said patient, a therapeutically effective amount of dalotuzumab. The invention also relates to methods for assessing neoplastic cells, selecting patients, selecting therapies as well as diagnostic methods.

摘要翻译： 本发明涉及在患者体内治疗达洛头沙坦反应性癌症的方法，包括测定来自患者的癌细胞中肝激酶B1（LKB1）的表达水平，并且当所述表达被确定为低于 控制细胞; 向所述患者施用治疗有效量的达洛托单抗。 本发明还涉及评估肿瘤细胞，选择患者，选择疗法以及诊断方法的方法。

公开(公告)号：US20130323232A1

公开(公告)日：2013-12-05

申请号：US13512061

申请日：2010-11-22

申请人： Sriram Sathyanarayanan ,  Christopher Winter ,  Youyuan Xu

发明人： Sriram Sathyanarayanan ,  Christopher Winter ,  Youyuan Xu

IPC分类号： G01N33/68 ,  A61N5/02 ,  A61N5/10 ,  A61N5/06 ,  A61K39/395 ,  A61K45/06

CPC分类号： G01N33/6893 ,  A61K39/39558 ,  A61K45/06 ,  A61N5/02 ,  A61N5/06 ,  A61N5/10 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/136 ,  G01N33/5044 ,  G01N33/5091 ,  G01N2333/475

摘要： Disclosed herein are methods of stratifying a patient population into an IGF-1R inhibitor responder or resistant population comprising assaying a sample of cells derived from a patient to determine if a cell from the patient sample is sensitive to treatment with an IGF-1R inhibitor and selecting a patient for treatment with an IGF-1R inhibitor if the cells from the patient are determined to be sensitive. The determination is based upon either the expression levels of wild type LKB1 in the patient sample wherein a low level of expression of the protein or the gene encoding the biomarker protein is predictive of a favorable outcome to an IGF-1R targeted therapy or detecting the presence of a loss of function mutant LKB1 in the sample, wherein presence of the mutant is predictive of a favorable outcome. The presence of the mutant may be accompanied by determining the expression level of IGF-1R in the same sample, wherein a concomitant increase in the level of expression of IGF-1R in addition to detecting the presence of the mutant protein also predicts a favorable outcome to an IGF-1R targeted therapy. Methods of treating a patient are also provided.

摘要翻译： 本文公开了将患者群体分层为IGF-1R抑制剂应答者或抗性群体的方法，包括测定来自患者的细胞样品，以确定来自患者样品的细胞是否对用IGF-1R抑制剂治疗敏感，并选择 如果来自患者的细胞被确定为敏感的，则用IGF-1R抑制剂治疗的患者。 该测定基于患者样品中野生型LKB1的表达水平，其中蛋白质的低水平表达或编码生物标记蛋白的基因预示出对IGF-1R靶向治疗的有利结果或检测存在 在样品中失去功能突变体LKB1，其中突变体的存在预示了有利的结果。 突变体的存在可以伴随着确定相同样品中IGF-1R的表达水平，其中除了检测突变蛋白的存在之外，IGF-1R的表达水平伴随增加也预示了有利的结果 到IGF-1R靶向治疗。 还提供了治疗患者的方法。